25 Aug 2020 Governance
Angela Smith-Morgan to step down from her role as Co CEO of Leukaemia UK
After eight successful years with us, Angela Smith-Morgan will be stepping down from her role as Co CEO of Leukaemia UK on 3rd September.
Angela was responsible for driving through the merger with Leuka in November 2019, and is now leaving the charity in a strong position to build on the remarkable transformation she engineered.
She has been a valued Co CEO of the merged charity and a visionary sole CEO of the original charity. We thank her for her outstanding work on our behalf and wish her the very best in the future.
Related posts
17 April 2024
“Every little thing is gonna be alright” – three little birds tattoo marks mum’s recovery from one of the least survivable cancers
New research by Leukaemia UK which could reduce the side-effects of treatment for acute myeloid leukaemia (AML) welcomed by family affected by the disease. A family who was devastated when…
25 November 2025
Improving access to life-changing treatment – Leukaemia UK’s role in the approval of Aucatzyl
Today, NICE announced its recommendation for Aucatzyl (obecabtagene autoleucel), a CAR-T therapy, to be made available on the NHS for treating adults aged 26 and over with relapsed or refractory…
4 July 2022
Cancer charities unite in encouraging the Government to address crucial issues as part of their “War on Cancer”
In collaboration with our partners and as part of the One Cancer Voice group, Cancer 52 and Blood Cancer Alliance, we have called on the Government to take account of a wide range of recommendations as they finalise the 10-Year Cancer Plan to be announced later this year.
10 January 2023
Clinical trial begins for pioneering new cancer treatment
Dr Konstantinos Tzelepis was awarded a Leukaemia UK research fellowship in 2020 and has developed a new class of cancer drug with the potential to treat leukaemia.